Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Transformed lymphoma: an Achilles' heel of non-Hodgkin's lymphoma

Bone Marrow Transplantation volume 31, pages 531–537 (2003)Cite this article

Summary:

Transformed lymphoma has a reported incidence of 10–70% among patients with follicular lymphoma. Interpreting the wide-ranging estimates for incidence, survival, and effects of interventions from various studies is complicated by the use of different definitions of lymphoma transformation. Problems in defining histologic transformation will be addressed in this review. To date, there are no reliable markers of risk for transformation or factors predictive of survival. The prognosis for transformed lymphoma is generally poor, with most patients surviving only a few months, though some with limited disease that is chemosensitive may experience prolonged survival. Immunotherapy, particularly monoclonal antibodies and radioimmunoconjugates, holds promise but more experience is necessary. Approximately 200 patients are included in published series of autologous transplantation; of these, one-third remain disease free at 5 years, not dissimilar to reported outcomes for nontransformed disease. However, the treatment-related mortality is higher than in nontransformed disease, and there is a significant incidence of post-transplant myelodysplastic syndrome. The role of allogeneic transplant has yet to be pursued, but should be explored for its potential for a graft-versus-lymphoma effect. Advances in microarray gene analysis and biology may facilitate the understanding of mechanisms of transformation, development of a prognostic index and creation of tailored therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Gall M . Malignant lymphoma. Am J Pathol 1942; 18: 381–415.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Rappaport H, Winter WJ, Hicks EB . Follicular lymphoma. Are-evaluation of its position in the scheme of malignant lymphoma based on survey of 253 cases. Cancer 1956; 9: 792–821.

    PubMed  Google Scholar 

  3. Isaacson PG . The current status of lymphoma classification. Br J Haematol 2000; 109: 258–266.

    CAS  PubMed  Google Scholar 

  4. Yuen AR, Kamel OW, Halpern J et al. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995; 13: 1726–1733.

    CAS  PubMed  Google Scholar 

  5. Bastion Y, Sebban C, Berger F et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997; 15: 1587–1594.

    CAS  PubMed  Google Scholar 

  6. Williams CD, Harrison CN, Lister TA et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001; 3: 727–735.

    Google Scholar 

  7. Hubbard SM, Chabner BA, DeVita VTJ et al. Histologic progression in non-Hodgkin's lymphoma. Blood 1982; 59: 258–264.

    CAS  PubMed  Google Scholar 

  8. Garvin AJ, Simon RM, Osborne CK et al. An autopsy study of histologic progression in non-Hodgkin's lymphomas: 192 cases from the National Cancer Institute. Cancer 1983; 52: 393–398.

    CAS  PubMed  Google Scholar 

  9. Horning SJ, Rosenberg SA . The natural history of initially untreated low-grade non-Hodgkin's lymphomas. New Engl J Med 1984; 311: 1471–1475.

    CAS  PubMed  Google Scholar 

  10. Tilly H, Rossi A, Stamatoullas A et al. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 1994; 84: 1043–1049.

    CAS  PubMed  Google Scholar 

  11. Matolcsy A, Casali P, Warnke RA, Knowles DM . Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated BCL2 gene. Blood 1996; 88: 3937–3944.

    CAS  PubMed  Google Scholar 

  12. Cory S, Adams JM . The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev 2002; 2: 647–656.

    CAS  Google Scholar 

  13. Armitage JO, Sanger WG, Weisenburger DD et al. Correlation of secondary cytogenetic abnormalities with histologic appearance in non-Hodgkin's lymphomas bearing t(14;18)(q32;q21). J Natl Cancer Inst 1988; 80: 576–580.

    CAS  PubMed  Google Scholar 

  14. Lee TJ, Innes DJ, Williams ME . Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin's lymphoma. J Clin Invest 1989; 84: 1454–1459.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Yano T, Jaffe ES, Longo DL, Raffeld M . Myc rearrangements in histologically progressed follicular lymphomas. Blood 1992; 80: 758–767.

    CAS  PubMed  Google Scholar 

  16. Lo Coco F, Giandano G, Louie DC . P53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 8: 2289–2295.

    Google Scholar 

  17. Sander CA, Yano T, Clark HM et al. P53 mutation is associated with progression in follicular lymphomas. Blood 1993; 80: 758–767.

    Google Scholar 

  18. Elenitoba-Johnson KS, Gascoyne RD, Lim MS et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998; 91: 4677–4685.

    CAS  PubMed  Google Scholar 

  19. Neat MJ, Foot N, Jenner M et al. Localisation of a novel region of recurrent amplification in follicular lymphoma to an approximately 6.8 Mb region of 13q32-33. Genes Chromosomes Cancer 2001; 32: 236–243.

    CAS  PubMed  Google Scholar 

  20. Lossos IS, Levy R . Higher-grade transformation of follicular center lymphoma is associated with somatic mutation of the 5' noncoding regulatory region of the BCL-6 gene. Blood 2000; 96: 635–639.

    CAS  PubMed  Google Scholar 

  21. Yano T, Sander CA, Andrade RE et al. Molecular analysis of the BCL-3 locus at chromosome 17q22 in B-cell neoplasms. Blood 1993; 82: 1813–1819.

    CAS  PubMed  Google Scholar 

  22. Robetorye RS, Bohling SD, Morgan JW et al. Microarray analysis of B-cell lymphoma cell lines with the t(14;18). J Mol Diagn 2002; 4: 123–136.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Lossos IS, Alizadeh AA, Diehn M et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA 2002; 99: 8886–8891.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Cohen Y, Da'as N, Libster D et al. Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine–rituximab-containing regimens: natural history- or therapy-related complication? Eur J Haematol 2002; 68: 80–83.

    CAS  PubMed  Google Scholar 

  25. Acker B, Hoppe RT, Colby TV et al. Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol 1983; 1: 11–16.

    CAS  PubMed  Google Scholar 

  26. Oviatt DL, Cousar JB, Collins RD et al. Malignant lymphoma of follicular center cell origin in humans V Incidence, clinical features, and prognostic implications of transformation of small cleaved cell nodular lymphoma. Cancer 1984; 53: 1109–1114.

    CAS  PubMed  Google Scholar 

  27. Cullen MH, Lister TA, Brearley RL et al. Histologic transformation of non-Hodgkin's lymphoma: a prospective study. Cancer 1983; 52: 645–651.

    Google Scholar 

  28. Horning SJ . Treatment approaches to the low-grade lymphomas. Blood 1994; 83: 881–884.

    CAS  PubMed  Google Scholar 

  29. Armitage JO, Dick FR, Corder MP . Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant. Cancer Treatment Rep 1981; 65: 413–418.

    CAS  Google Scholar 

  30. Witzig TE, Gordon LI, Cabanillas F . Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453–2463.

    CAS  PubMed  Google Scholar 

  31. Kaminski MS, Estes J, Zasadny KR et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259–1266.

    CAS  PubMed  Google Scholar 

  32. Vose JM, Wahl RL, Saleh M et al. Multicenter phase II study of iodine-131 tositumamab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000; 18: 1316–1323.

    CAS  PubMed  Google Scholar 

  33. Press OW, Eary JF, Gooley T et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934–2942.

    CAS  PubMed  Google Scholar 

  34. Czuczman MS, Grillo-Lopez AJ, McLaughlin P et al. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol 2001; 12: 109–114.

    CAS  PubMed  Google Scholar 

  35. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106.

    CAS  PubMed  Google Scholar 

  36. Schouten HC, Bierman PJ, Vaughan WP et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 1989; 74: 2579–2584.

    CAS  PubMed  Google Scholar 

  37. Freedman AS, Ritz J, Neuberg D et al. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood 1991; 77: 2524–2529.

    CAS  PubMed  Google Scholar 

  38. Friedberg JW, Newberg D, Gribben JG . Autologous bone marrow transplantation after histologic transformation of indolent B-cell malignancies. Biol Blood Marrow Transplant 1999; 5: 262–268.

    CAS  PubMed  Google Scholar 

  39. Bastion Y, Brice P, Haioun C et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86: 3257–3262.

    CAS  PubMed  Google Scholar 

  40. Foran JM, Apostolidis J, Papamichael D et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol 1998; 9: 865–869.

    CAS  PubMed  Google Scholar 

  41. Berglund A, Enblad G, Carlson K et al. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. Eur J Haematol 2000; 65: 17–22.

    CAS  PubMed  Google Scholar 

  42. Cao TM, Horning S, Negrin RS . High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001; 7: 294–301.

    CAS  PubMed  Google Scholar 

  43. Chen CI, Crump M, Tsang R et al. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol 2001; 113: 202–208.

    CAS  PubMed  Google Scholar 

  44. Le Gouill S, Moreau P, Morineau N et al. Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study. Haematologica 2002; 87: 333–334.

    PubMed  Google Scholar 

  45. Williams CD, Goldstone AH, Pearce RM et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14: 2454–2464.

    CAS  PubMed  Google Scholar 

  46. Weisdorf DJ, Haake R, Miller WJ et al. Autologous bone marrow transplantation for progressive non-Hodgkin's lymphoma: clinical impact of immunophenotype and in vitro purging. Bone Marrow Transplant 1991; 8: 135–142.

    CAS  PubMed  Google Scholar 

  47. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333.

    CAS  PubMed  Google Scholar 

  48. Bierman PJ, Sweetenham JW, Loberiza FM et al. Syngeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma (NHL): comparison with allogeneic and autologous transplants suggests a role for purging. ASCO Proceedings 2001; 20: 5a (abstract 15).

    Google Scholar 

  49. Johnson PW, Price CG, Smith T et al. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1994; 12: 798–805.

    CAS  PubMed  Google Scholar 

  50. Hunault-Berger M, Ifrah N, Solal-Celigny P . Intensive therapies in follicular non-Hodgkin's lymphomas. Blood 2002; 100: 1141–1152.

    CAS  PubMed  Google Scholar 

  51. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    CAS  PubMed  Google Scholar 

  52. Miller JS, Arthur DC, Litz CE et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994; 83: 3780–3786.

    CAS  PubMed  Google Scholar 

  53. Friedberg JW, Neuberg D, Stone RM et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128–3135.

    CAS  PubMed  Google Scholar 

  54. van Besien K, Sobocinski KA, Rowlings PA et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832–1836.

    CAS  PubMed  Google Scholar 

  55. Verdonck LF, Dekker AW, Lokhurst HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201–4205.

    CAS  PubMed  Google Scholar 

  56. Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595–3599.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and the Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA

    R E Lerner & L J Burns

Authors
  1. R E Lerner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L J Burns
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lerner, R., Burns, L. Transformed lymphoma: an Achilles' heel of non-Hodgkin's lymphoma. Bone Marrow Transplant 31, 531–537 (2003). https://doi.org/10.1038/sj.bmt.1703875

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703875

Keywords

This article is cited by

Search

Advanced search

Quick links